Background
Methods
Patient selection and clinicopathologic evaluation
Tissue microarray (TMA)
Immunohistochemistry (IHC)
Interpretation of immunohistochemical results
Statistical analysis
Results
Basal characteristics of PUMC patients according to the histologic subtypes
Clinical parameters | Total N = 77 (%) | Histologic subtype | p-value | |||
---|---|---|---|---|---|---|
AD (n = 27) (%) | PD (n = 16) (%) | SQ (n = 20) (%) | UD (n = 14) (%) | |||
Age (years, mean ± SD) | 55.4 ± 11.8 | 59.3 ± 12.3 | 55.3 ± 12.1 | 55.0 ± 9.6 | 48.3 ± 10.6 | 0.042 |
Sex | 0.521 | |||||
Female | 29 (37.7) | 13 (48.1) | 6 (37.5) | 6 (30.0) | 4 (28.6) | |
Male | 48 (62.3) | 14 (51.9) | 10 (62.5) | 14 (70.0) | 10 (71.4) | |
Clinical subtype |
<0.001
| |||||
Nodal type | 34 (44.2) | 3 (11.1) | 8 (50.0) | 14 (70.0) | 9 (64.3) | |
Single organ type | 15 (19.5) | 6 (22.2) | 5 (31.3) | 0 (0.0) | 4 (28.6) | |
Intermediate type | 14 (18.2) | 7 (25.9) | 1 (6.3) | 5 (25.0) | 1 (7.1) | |
Carcinomatosis type | 14 (18.2) | 11 (40.7) | 2 (12.5) | 1 (5.0) | 0 (0.0) | |
Organs involved | 0.102 | |||||
Lymph node | 49 (63.6) | 12 (44.4) | 9 (56.3) | 19 (95.0) | 9 (64.3) | |
Bone | 10 (13.0) | 6 (22.2) | 2 (12.5) | 0 (0.0) | 2 (14.3) | |
Brain | 9 (11.7) | 4 (14.8) | 2 (12.5) | 1 (5.0) | 2 (14.3) | |
Other | 9 (11.7) | 5 (18.5) | 3 (18.8) | 0 (0.0) | 1 (7.1) | |
Postoperative treatment | 0.039 | |||||
None | 21 (27.3) | 8 (29.6) | 3 (18.8) | 4 (20.0) | 6 (42.9) | |
Chemotherapy | 24 (31.2) | 12 (44.4) | 5 (31.3) | 3 (15.0) | 4 (28.6) | |
Radiation therapy | 15 (19.5) | 6 (22.2) | 1 (6.3) | 6 (30.0) | 2 (14.3) | |
Chemo-radiation therapy | 17 (22.1) | 1 (3.7) | 7 (43.8) | 7 (35.0) | 2 (14.3) |
Expression of metabolism-related proteins in PUMC according to the histologic and clinical subtype
Immunohistochemical parameters | Total N = 77 (%) | Histologic subtype | p-value | |||
---|---|---|---|---|---|---|
AD (n = 27) (%) | PD (n = 16) (%) | SQ (n = 20) (%) | UD (n = 14) (%) | |||
Glut-1 (T) |
0.028
| |||||
Negative | 41 (53.2) | 17 (63.0) | 11 (68.8) | 5 (25.0) | 8 (57.1) | |
Positive | 36 (46.8) | 10 (37.0) | 5 (31.3) | 15 (75.0) | 6 (42.9) | |
Glut-1 (S) | N/A | |||||
Negative | 77 (100.0) | 27 (100.0) | 16 (100.0) | 20 (100.0) | 14 (100.0) | |
Positive | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
CAIX (T) | 0.124 | |||||
Negative | 68 (88.3) | 24 (88.9) | 15 (93.8) | 15 (75.0) | 14 (100.0) | |
Positive | 9 (11.7) | 3 (11.1) | 1 (6.3) | 5 (25.0) | 0 (0.0) | |
CAIX (S) |
0.050
| |||||
Negative | 75 (97.4) | 27 (100.0) | 14 (87.5) | 20 (100.0) | 14 (100.0) | |
Positive | 2 (2.6) | 0 (0.0) | 2 (12.5) | 0 (0.0) | 0 (0.0) | |
MCT4 (T) | 0.409 | |||||
Negative | 22 (28.6) | 8 (29.6) | 7 (43.8) | 4 (20.0) | 3 (21.4) | |
Positive | 55 (71.4) | 19 (70.4) | 9 (56.3) | 16 (80.0) | 11 (78.6) | |
MCT4 (S) | 0.902 | |||||
Negative | 43 (55.8) | 15 (55.6) | 10 (62.5) | 10 (50.0) | 8 (57.1) | |
Positive | 34 (44.2) | 12 (44.4) | 6 (37.5) | 10 (50.0) | 6 (42.9) | |
GLS1 (T) | 0.184 | |||||
Negative | 46 (59.7) | 14 (51.9) | 11 (68.8) | 15 (75.0) | 6 (42.9) | |
Positive | 31 (40.3) | 13 (48.1) | 5 (31.3) | 5 (25.0) | 8 (57.1) | |
GLS1 (S) | 0.401 | |||||
Negative | 68 (88.3) | 23 (85.2) | 13 (81.3) | 18 (90.0) | 14 (100.0) | |
Positive | 9 (11.7) | 4 (14.8) | 3 (18.8) | 2 (10.0) | 0 (0.0) | |
GDH (T) | 0.510 | |||||
Negative | 8 (10.4) | 2 (7.4) | 3 (18.8) | 1 (5.0) | 2 (14.3) | |
Positive | 69 (89.6) | 25 (92.6) | 13 (81.3) | 19 (95.0) | 12 (85.7) | |
GDH (S) | 0.350 | |||||
Negative | 58 (75.3) | 18 (66.7) | 11 (68.8) | 17 (85.0) | 12 (85.7) | |
Positive | 19 (24.7) | 9 (33.3) | 5 (31.3) | 3 (15.0) | 2 (14.3) | |
ASCT2 (T) | 0.413 | |||||
Negative | 47 (61.0) | 15 (55.6) | 8 (50.0) | 15 (75.0) | 9 (64.3) | |
Positive | 30 (39.0) | 12 (44.4) | 8 (50.0) | 5 (25.0) | 5 (35.7) | |
ASCT2 (S) | 0.313 | |||||
Negative | 73 (94.8) | 24 (88.9) | 16 (100.0) | 19 (95.0) | 14 (100.0) | |
Positive | 4 (5.2) | 3 (11.1) | 0 (0.0) | 1 (5.0) | 0 (0.0) | |
ATP synthase (T) | 0.597 | |||||
Negative | 2 (2.6) | 1 (3.7) | 1 (6.3) | 0 (0.0) | 0 (0.0) | |
Positive | 75 (97.4) | 26 (96.3) | 15 (93.8) | 20 (100.0) | 14 (100.0) | |
ATP synthase (S) | 0.101 | |||||
Negative | 62 (80.5) | 18 (66.7) | 13 (81.3) | 19 (95.0) | 12 (85.7) | |
Positive | 15 (19.5) | 9 (33.3) | 3 (18.8) | 1 (5.0) | 2 (14.3) | |
SDHA (T) | 0.208 | |||||
Negative | 3 (3.9) | 1 (3.7) | 2 (12.5) | 0 (0.0) | 0 (0.0) | |
Positive | 74 (96.1) | 26 (96.3) | 14 (87.5) | 20 (100.0) | 14 (100.0) | |
SDHA (S) | 0.200 | |||||
Negative | 59 (76.6) | 17 (63.0) | 14 (87.5) | 16 (80.0) | 12 (85.7) | |
Positive | 18 (23.4) | 10 (37.0) | 2 (12.5) | 4 (20.0) | 2 (14.3) | |
SDHB (T) | 0.112 | |||||
Negative | 28 (36.4) | 7 (25.9) | 9 (56.3) | 9 (45.0) | 3 (21.4) | |
Positive | 49 (63.6) | 20 (74.1) | 7 (43.8) | 11 (55.0) | 11 (78.6) | |
SDHB (S) |
0.025
| |||||
Negative | 66 (85.7) | 19 (70.4) | 15 (93.8) | 20 (100.0) | 12 (85.7) | |
Positive | 11 (14.3) | 8 (29.6) | 1 (6.3) | 0 (0.0) | 2 (14.3) |
Immunohistochemical parameters | Total (n = 77) (%) | Clinical subtype | p-value | |||
---|---|---|---|---|---|---|
Nodal type (n = 34) (%) | Single organ type (n = 15) (%) | Intermediate type (n = 14) (%) | Carcinomatosis type (n = 14)(%) | |||
Glut-1 (T) |
0.021
| |||||
Negative | 41 (53.2) | 13 (38.2) | 9 (60.0) | 9 (64.3) | 10 (71.4) | |
Positive | 36 (46.8) | 21 (61.8) | 6 (40.0) | 5 (35.7) | 4 (28.6) | |
Glut-1 (S) | N/A | |||||
Negative | 77 (100.0) | 34 (100.0) | 15 (100.0) | 14 (100.0) | 14 (100.0) | |
Positive | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
CAIX (T) | 0.372 | |||||
Negative | 68 (88.3) | 28 (82.4) | 15 (100.0) | 12 (85.7) | 13 (92.9) | |
Positive | 9 (11.7) | 6 (17.6) | 0 (0.0) | 2 (14.3) | 1 (7.1) | |
CAIX (S) | 0.458 | |||||
Negative | 75 (97.4) | 33 (97.1) | 14 (93.3) | 14 (100.0) | 14 (100.0) | |
Positive | 2 (2.6) | 1 (2.9) | 1 (6.7) | 0 (0.0) | 0 (0.0) | |
MCT4 (T) | 0.877 | |||||
Negative | 22 (28.6) | 11 (32.4) | 2 (13.3) | 4 (28.6) | 5 (35.7) | |
Positive | 55 (71.4) | 23 (67.6) | 13 (86.7) | 10 (71.4) | 9 (64.3) | |
MCT4 (S) | 0.372 | |||||
Negative | 43 (55.8) | 17 (50.0) | 9 (60.0) | 8 (57.1) | 9 (64.3) | |
Positive | 34 (44.2) | 17 (50.0) | 6 (40.0) | 6 (42.9) | 5 (35.7) | |
GLS1 (T) | 0.176 | |||||
Negative | 46 (59.7) | 23 (67.6) | 8 (53.3) | 9 (64.3) | 6 (42.9) | |
Positive | 31 (40.3) | 11 (32.4) | 7 (46.7) | 5 (35.7) | 8 (57.1) | |
GLS1 (S) | 0.123 | |||||
Negative | 68 (88.3) | 31 (91.2) | 14 (93.3) | 13 (92.9) | 10 (71.4) | |
Positive | 9 (11.7) | 3 (8.8) | 1 (6.7) | 1 (7.1) | 4 (28.6) | |
GDH (T) | 0.181 | |||||
Negative | 8 (10.4) | 2 (5.9) | 2 (13.3) | 1 (7.1) | 3 (21.4) | |
Positive | 69 (89.6) | 32 (94.1) | 13 (86.7) | 13 (92.9) | 11 (78.6) | |
GDH (S) | 0.816 | |||||
Negative | 58 (75.3) | 27 (79.4) | 10 (66.7) | 10 (71.4) | 11 (78.6) | |
Positive | 19 (24.7) | 7 (20.6) | 5 (33.3) | 4 (28.6) | 3 (21.4) | |
ASCT2 (T) | 0.823 | |||||
Negative | 47 (61.0) | 19 (55.9) | 11 (73.3) | 9 (64.3) | 8 (57.1) | |
Positive | 30 (39.0) | 15 (44.1) | 4 (26.7) | 5 (35.7) | 6 (42.9) | |
ASCT2 (S) | 0.255 | |||||
Negative | 73 (94.8) | 33 (97.1) | 15 (100.0) | 12 (85.7) | 13 (92.9) | |
Positive | 4 (5.2) | 1 (2.9) | 0 (0.0) | 2 (14.3) | 1 (7.1) | |
ATP synthase (T) | 0.626 | |||||
Negative | 2 (2.6) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 1 (7.1) | |
Positive | 75 (97.4) | 33 (97.1) | 15 (100.0) | 14 (100.0) | 13 (92.9) | |
ATP synthase (S) | 0.395 | |||||
Negative | 62 (80.5) | 29 (85.3) | 11 (73.3) | 12 (85.7) | 10 (71.4) | |
Positive | 15 (19.5) | 5 (14.7) | 4 (26.7) | 2 (14.3) | 4 (28.6) | |
SDHA (T) | 0.393 | |||||
Negative | 3 (3.9) | 1 (2.9) | 0 (0.0) | 1 (7.1) | 1 (7.1) | |
Positive | 74 (96.1) | 33 (97.1) | 15 (100.0) | 13 (92.9) | 13 (92.9) | |
SDHA (S) | 0.794 | |||||
Negative | 59 (76.6) | 27 (79.4) | 11 (73.3) | 10 (71.4) | 11 (78.6) | |
Positive | 18 (23.4) | 7 (20.6) | 4 (26.7) | 4 (28.6) | 3 (21.4) | |
SDHB (T) | 0.230 | |||||
Negative | 28 (36.4) | 16 (47.1) | 3 (20.0) | 5 (35.7) | 4 (28.6) | |
Positive | 49 (63.6) | 18 (52.9) | 12 (80.0) | 9 (64.3) | 10 (71.4) | |
SDHB (S) | 0.968 | |||||
Negative | 66 (85.7) | 30 (88.2) | 11 (73.3) | 13 (92.9) | 12 (85.7) | |
Positive | 11 (14.3) | 4 (11.8) | 4 (26.7) | 1 (7.1) | 2 (14.3) |
Correlation between metabolic phenotypes of tumor clinicopathologic factors
Parameters | Glycolysis type | Glutaminolysis type | Mitochondrial type | ||||||
---|---|---|---|---|---|---|---|---|---|
Yes | No | p-value | Yes | No | p-value | Yes | No | p-value | |
n = 33 (%) | n = 44 (%) | n = 43 (%) | n = 34 (%) | n = 74 (%) | n = 3 (%) | ||||
Age | 0.087 | 0.340 | 1.000 | ||||||
<50 | 7 (21.2) | 18 (40.9) | 16 (37.2) | 9 (26.5) | 24 (32.4) | 1 (33.3) | |||
≥50 | 26 (78.8) | 26 (59.1) | 27 (62.8) | 25 (73.5) | 50 (67.6) | 2 (66.7) | |||
Sex | 0.342 | 1.000 | 1.000 | ||||||
Male | 23 (69.7) | 25 (56.8) | 27 (62.8) | 21 (61.8) | 46 (62.2) | 2 (66.7) | |||
Female | 10 (30.3) | 19 (43.2) | 16 (37.2) | 13 (38.2) | 28 (37.8) | 1 (33.3) | |||
Clinical subtype | 0.371 | 0.971 | 0.687 | ||||||
Nodal type | 18 (54.5) | 16 (36.4) | 18 (41.9) | 16 (47.1) | 33 (44.6) | 1 (33.3) | |||
Single organ type | 5 (15.2) | 10 (22.7) | 9 (20.9) | 6 (17.6) | 15 (20.3) | 0 (0.0) | |||
Intermediate type | 6 (18.2) | 8 (18.2) | 8 (18.6) | 6 (17.6) | 13 (17.6) | 1 (33.3) | |||
Carcinomatosis type | 4 (12.1) | 10 (22.7) | 8 (18.6) | 6 (17.6) | 13 (17.6) | 1 (33.3) | |||
Histologic type | 0.093 | 0.545 | 0.208 | ||||||
AD | 11 (33.3) | 16 (36.4) | 17 (39.5) | 10 (29.4) | 26 (35.1) | 1 (33.3) | |||
PD | 4 (12.1) | 12 (27.3) | 8 (18.6) | 8 (23.5) | 14 (18.9) | 2 (66.7) | |||
SQ | 13 (39.4) | 7 (15.9) | 9 (20.9) | 11 (32.4) | 20 (27.0) | 0 (0.0) | |||
UP | 5 (15.2) | 9 (20.5) | 9 (20.9) | 5 (14.7) | 14 (18.9) | 0 (0.0) | |||
Organs involved | 0.392 | 0.730 |
0.026
| ||||||
Lymph node | 24 (72.7) | 25 (56.8) | 27 (62.8) | 22 (64.7) | 48 (64.9) | 1 (33.3) | |||
Bone | 3 (9.1) | 7 (15.9) | 7 (16.3) | 3 (8.8) | 10 (13.5) | 0 (0.0) | |||
Brain | 4 (12.1) | 5 (11.4) | 4 (9.3) | 5 (14.7) | 9 (12.2) | 0 (0.0) | |||
Other | 2 (6.1) | 7 (15.9) | 5 (11.6) | 4 (11.8) | 7 (9.5) | 2 (66.7) |
Parameters | Glycolysis type | Glutaminolysis type | Mitochondrial type | ||||||
---|---|---|---|---|---|---|---|---|---|
Yes | No | p-value | Yes | No | p-value | Yes | No | p-value | |
n = 2 (%) | n = 75 (%) | n = 8 (%) | n = 69 (%) | n = 74 (%) | n = 3 (%) | ||||
Age | 0.547 | 0.710 | 0.741 | ||||||
<50 | 1 (50.0) | 24 (32.0) | 3 (37.5) | 22 (31.9) | 3 (25.0) | 22 (33.8) | |||
≥50 | 1 (50.0) | 51 (68.0) | 5 (62.5) | 47 (68.1) | 9 (75.0) | 43 (66.2) | |||
Sex | 0.524 | 0.466 | 0.351 | ||||||
Male | 2 (100.0) | 46 (61.3) | 4 (50.0) | 44 (63.8) | 6 (50.0) | 42 (64.6) | |||
Female | 0 (0.0) | 29 (38.7) | 4 (50.0) | 25 (36.2) | 6 (50.0) | 23 (35.4) | |||
Clinical subtype | 0.627 | 0.857 | 0.533 | ||||||
Nodal type | 1 (50.0) | 33 (44.0) | 3 (37.5) | 31 (44.9) | 5 (41.7) | 29 (44.6) | |||
Single organ type | 1 (50.0) | 14 (18.7) | 1 (12.5) | 14 (20.3) | 4 (33.3) | 11 (16.7) | |||
Intermediate type | 0 (0.0) | 14 (18.7) | 2 (25.0) | 12 (17.4) | 1 (8.3) | 13 (20.0) | |||
Carcinomatosis type | 0 (0.0) | 14 (18.7) | 2 (25.0) | 12 (17.4) | 2 (16.7) | 12 (18.5) | |||
Histologic type |
0.050
| 0.237 |
0.049
| ||||||
AD | 0 (0.0) | 27 (36.0) | 5 (62.5) | 22 (31.9) | 8 (66.7) | 19 (29.2) | |||
PD | 2 (100.0) | 14 (18.7) | 2 (25.0) | 14 (20.3) | 2 (16.7) | 14 (21.5) | |||
SQ | 0 (0.0) | 20 (26.7) | 1 (12.5) | 19 (27.5) | 0 (0.0) | 20 (30.8) | |||
UP | 0 (0.0) | 14 (18.7) | 0 (0.0) | 14 (20.3) | 2 (16.7) | 12 (18.5) | |||
Organs involved | 0.439 |
0.003
| 0.121 | ||||||
Lymph node | 1 (50.0) | 48 (64.0) | 4 (50.0) | 45 (65.2) | 6 (50.0) | 43 (66.2) | |||
Bone | 1 (50.0) | 9 (12.0) | 0 (0.0) | 10 (14.5) | 3 (25.0) | 7 (10.8) | |||
Brain | 0 (0.0) | 9 (12.0) | 0 (0.0) | 9 (13.0) | 0 (0.0) | 9 (13.8) | |||
Other | 0 (0.0) | 9 (12.0) | 4 (50.0) | 5 (7.2) | 3 (25.0) | 6 (9.2) |
Glycolysis type (T) | Glutaminolysis type (T) | Mitochondrial type (T) | Glycolysis type (S) | Glutaminolysis type (S) | Mitochondrial type (S) | |
---|---|---|---|---|---|---|
Glycolysis type (T) | ||||||
Correlation coefficient | -0.075 | 0.175 | -0.141 | -0.037 | -0.083 | |
p-value | 0.514 | 0.129 | 0.220 | 0.750 | 0.475 | |
Glutaminolysis type (T) | ||||||
Correlation coefficient | 0.226 | 0.145 | 0.046 | 0.094 | ||
p-value |
0.048
| 0.208 | 0.693 | 0.418 | ||
Mitochondrial type (T) | ||||||
Correlation coefficient | 0.033 | -0.151 | 0.087 | |||
p-value | 0.777 | 0.189 | 0.454 | |||
Glycolysis type (S) | ||||||
Correlation coefficient | 0.212 | 0.155 | ||||
p-value | 0.064 | 0.178 | ||||
Glutaminolysis type (S) | ||||||
Correlation coefficient | 0.558 | |||||
p-value |
<0.001
|
Correlation between the expression of glycolysis related proteins and that of mitochondrial metabolism related proteins according to the histologic and clinical subtypes
Impact of clinicopathologic and immunohistochemical factors on prognosis
Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | ||
---|---|---|---|---|
No. of cases | Patient death | Median survival (95% CI) (months) | P -value | |
Age | 0.326 | |||
<50 | 20 | 5 | 96 (70–123) | |
≥50 | 39 | 13 | 43 (30–56) | |
Sex | 0.539 | |||
Male | 35 | 10 | 88 (65–110) | |
Female | 24 | 8 | 74 (44–103) | |
Histologic subtype |
0.002
| |||
AD | 21 | 11 | 23 (10–36) | |
PD | 13 | 1 | 34 (28–40) | |
SQ | 17 | 5 | 49 (33–65) | |
UD | 8 | 1 | 115 (86–145) | |
Clinical subtype |
<0.001
| |||
Nodal type | 25 | 3 | 107 (88–126) | |
Single organ type | 10 | 1 | 119 (95–143) | |
Intermediate type | 10 | 4 | 21 (9–32) | |
Carcinomatosis type | 14 | 10 | 6 (3–10) | |
Organs involved | 0.701 | |||
Lymph node | 38 | 12 | 77 (55–99) | |
Bone | 6 | 2 | 40 (18–62) | |
Brain | 7 | 1 | 31 (23–39) | |
Other | 8 | 3 | 83 (40–126) | |
Postoperative treatment | 0.638 | |||
None | 7 | 1 | 107 (75–139) | |
Chemotherapy | 20 | 7 | 77 (45–108) | |
Radiation therapy | 15 | 4 | 52 (36–68) | |
Chemo-radiation therapy | 17 | 6 | 25 (18–33) |
Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | |||
---|---|---|---|---|---|
No. of cases | Patient death | Median survival (95% CI) (months) | P -value | ||
Glut-1 (T) | 0.101 | ||||
Negative | 34 | 13 | 74 (49–98) | ||
Positive | 25 | 5 | 55 (42–68) | ||
Glut-1 (S) | N/A | N/A | |||
Negative | 59 | 18 | 84 (66–102) | ||
Positive | 0 | 0 | N/A | ||
CAIX (T) | 0.272 | ||||
Negative | 51 | 17 | 82 (63–101) | ||
Positive | 8 | 1 | 54 (30–79) | ||
CAIX (S) | N/A | ||||
Negative | 57 | 18 | N/A | ||
Positive | 2 | 0 | N/A | ||
MCT4 (T) | 0.759 | ||||
Negative | 19 | 5 | 87 (59–115) | ||
Positive | 40 | 13 | 80 (57–103) | ||
MCT4 (S) | 0.631 | ||||
Negative | 34 | 9 | 94 (73–115) | ||
Positive | 25 | 9 | 43 (29–57) | ||
GLS1 (T) | 0.139 | ||||
Negative | 39 | 10 | 49 (38–60) | ||
Positive | 20 | 8 | 73 (42–103) | ||
GLS1 (S) | 0.721 | ||||
Negative | 50 | 15 | 84 (65–104) | ||
Positive | 9 | 3 | 46 (22–69) | ||
GDH (T) | 1.000 | ||||
Negative | 7 | 2 | 28 (14–39) | ||
Positive | 52 | 16 | 85 (66–104) | ||
GDH (S) | 0.786 | ||||
Negative | 44 | 13 | 90 (72–109) | ||
Positive | 15 | 5 | 40 (19–60) | ||
ASCT2 (T) | 0.506 | ||||
Negative | 38 | 13 | 78 (54–101) | ||
Positive | 21 | 5 | 36 (27–45) | ||
ASCT2 (S) | 0.227 | ||||
Negative | 56 | 16 | 87 (68–105) | ||
Positive | 3 | 2 | 16 (1–32) | ||
ATP synthase (T) | 0.653 | ||||
Negative | 2 | 1 | 10 (10–10) | ||
Positive | 57 | 17 | 85 (67–104) | ||
ATP synthase (S) | 0.535 | ||||
Negative | 48 | 14 | 88 (68–107) | ||
Positive | 11 | 4 | 23 (12–34) | ||
SDHA (T) | 0.906 | ||||
Negative | 3 | 1 | 28 (13–43) | ||
Positive | 56 | 17 | 84 (66–103) | ||
SDHA (S) | 0.588 | ||||
Negative | 44 | 13 | 90 (70–109) | ||
Positive | 15 | 5 | 37 (15–58) | ||
SDHB (T) | 0.166 | ||||
Negative | 23 | 5 | 86 (56–115) | ||
Positive | 36 | 13 | 79 (57–102) | ||
SDHB (S) | 0.923 | ||||
Negative | 51 | 16 | 84 (65–103) | ||
Positive | 8 | 2 | 27 (16–37) |
Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | ||
---|---|---|---|---|
No. of cases | Patient death | Median survival (95% CI) (months) | P -value | |
Tumor metabolic type | 0.279 | |||
Glycolysis type | 22 | 5 | 52 (37–67) | |
Non-glycolysis type | 37 | 13 | 79 (56–102) | |
Tumor metabolic type | 0.644 | |||
Glutaminolysis type | 30 | 10 | 84 (60–108) | |
Non-glutaminolysis type | 29 | 8 | 45 (30–59) | |
Tumor metabolic type | 0.906 | |||
Mitochondrial type | 56 | 17 | 84 (66–103) | |
Non-mitochondrial type | 3 | 1 | 28 (13–43) | |
Stroma metabolic type | n/a | |||
Glycolysis type | 2 | 0 | n/a | |
Non-glycolysis type | 57 | 18 | n/a | |
Stroma metabolic type | 0.363 | |||
Glutaminolysis type | 7 | 1 | 62 (43–80) | |
Non-glutaminolysis type | 52 | 17 | 80 (60–100) | |
Stroma metabolic type | 0.864 | |||
Mitochondrial type | 9 | 2 | 28 (18–37) | |
Non-mitochondrial type | 50 | 16 | 83 (64–103) |